Title |
Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma
|
---|---|
Published in |
Journal for Immunotherapy of Cancer, June 2017
|
DOI | 10.1186/s40425-017-0250-5 |
Pubmed ID | |
Authors |
Gustavo Schvartsman, Kristen Perez, Jill E. Flynn, Jeffrey N. Myers, Hussein Tawbi |
Abstract |
Immunotherapy plays a key role in the treatment of metastatic melanoma. Patients with autoimmune conditions and/or on immunosuppressive therapy due to orthotropic transplants, however, are systematically excluded from clinical trials. Talimogene laherparepvec (T-VEC) is the first oncolytic virus to be approved by the FDA for cancer therapy. To our knowledge, this is the first report of T-VEC being administered in the setting of an organ transplant recipient. Here we present the case of a patient with recurrent locally advanced cutaneous melanoma receiving salvage T-VEC therapy in the setting of orthotropic heart transplantation. After 5 cycles of therapy, no evidence of graft rejection has been observed to date, and the patient achieved a complete remission, and is currently off therapy. This case advocates for further investigation on the safety and efficacy of immunotherapeutic approaches, such as T-VEC, in solid organ transplant recipients. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 4 | 27% |
Belgium | 2 | 13% |
France | 1 | 7% |
Brazil | 1 | 7% |
Mexico | 1 | 7% |
Unknown | 6 | 40% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 10 | 67% |
Practitioners (doctors, other healthcare professionals) | 3 | 20% |
Science communicators (journalists, bloggers, editors) | 2 | 13% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 49 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 12 | 24% |
Researcher | 6 | 12% |
Student > Master | 5 | 10% |
Student > Doctoral Student | 3 | 6% |
Other | 2 | 4% |
Other | 7 | 14% |
Unknown | 14 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 16 | 33% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
Biochemistry, Genetics and Molecular Biology | 3 | 6% |
Agricultural and Biological Sciences | 3 | 6% |
Mathematics | 2 | 4% |
Other | 5 | 10% |
Unknown | 17 | 35% |